Large-scale testing (Phase 3)Study completedNCT01777308
What this trial is testing
Immunogenicity, Reactogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' MenACWY-TT Vaccine Administered 6 Years Post-MenC Primary Vaccination in Healthy Subjects Who Were 12-18 Months at Primary Vaccination
Who this might be right for
Infections, Meningococcal
GlaxoSmithKline 156